flanders.bio member events

EIT Health comprises a powerful network of entrepreneurs, formal and informal investors, key-opinion leaders and innovation executives that enable and empower the next (international) step of ventures. The EIT Health Investor Network facilitates private capital match with promising investment-ready start-ups and scale-ups.

The EIT Health Partners and the EIT Health Investor Network are pleased to announce the 2018 Investor Forum on 26 September in Leuven, Belgium. The focus will be on Regenerative Medicine / Biotechnology / Food for Health.

For any life sciences company bringing its first product to market, the “commercialization to-do list” is long and punctuated by one critical strategic decision after another. What are the variables driving your launch strategy? What tools should you have in place to support marketing and sales? How can you ensure compliant transparency reporting and mitigate risk? Often in as little as 18 months, you’ll need to pull together – or access – an entire commercial organization and infrastructure. So where do you start?

The next Naturejobs Career Expo will be on October 4th, 2018.

This R&D seminar will address the new early phase clinical trials paradigm through two main topics: "How to choose the right early phase clinical study design" and "Empowering early phase R&D with human challenge trial solutions".

You’re in the early development stages, and of course, you are focused on safety, efficacy and quality of your product; however, positive results in all these areas doesn’t necessarily guarantee success. An often-overlooked hurdle in early product development is a strategic market access plan.

On October 11th 2018 Flanders Vaccine is happy to host its third edition of “Immunity for Health”: the Flanders Vaccine annual flagship event where all stakeholders, both from human and animal health sector, working in the field of immunology, vaccinology, immune-oncology and infectious diseases are invited to meet and interact.

This year on Sunday October 14th, Vanessa Delacourt will run the ‘20km de Paris’. Already in 1979, 8.000 runners set off at the start of the very
first ‘20km de Paris’. This year an estimated 30.000 runners will attend the 40th anniversary of this prestigious run. The run starts at Pont d’Iena and then heads towards the Bois de Boulogne before reaching the finish line at the foot of the Eiffel Tower.

• Our purpose is to motivate 100 managers and all sympathizers to run with Vanessa.
• By sponsoring your favourite runner, you support the4Brain Research Team
• Gifts of 40 euro or higher are tax-deductible
• Our target is to collect at least 100K.

This free ELIXIR Innovation and SME Forum on Data Driven Innovation in Industrial Biotechnology in Frankfurt is open to both large and small companies and aims to inform about ELIXIR resources and create a space to network for industry and academia.

Kom tijdens VIB biotechdag op 21 oktober in Antwerpen meer te weten over ‘Geneeskunde op maat‘

If you use human samples or human cell lines for your research, you'll need to register your organisation as an official BIOBANK with FAMHP. What are the different steps? Who should be involved and how?

With over 200 biopharma/biotech companies operating in Belgium (8-10% of all such companies in Europe), the Belgian biopharma/biotech companies account for 16% of Europe’s turnover and almost 10% of R&D expenditure.

Universities played and are playing a key role in technology transfer with strong collaboration between their various departments resulting in intensive exchanges of knowledge and ultimately driving further development in the sector. Spin-off biopharma/biotech companies are springing up all over Belgium with all regions (Flanders, Wallonia and Brussels) very active in the sector.

But what is next?

The business development professional's purpose is to optimize optionality and long-term value at each stage of a company's life. As a company grows and gains traction, it's easy to get enticed and overwhelmed by the numerous opportunities that arise. How do you determine the direction that will add the most value to your company? How do you avoid the constant pursuit of "shiny objects?" How do you know when it's the right time for a strategic partnership?

Are you a high tech SME, an Applied Research Institute or a Start-up offering innovative and breakthrough solutions for medical technologies? Then Boston Scientific, global medical technology leader, wants to explore an active partnership with you.

Along with the enormous promise, there’s a lot of uncharted territory in the world of Microbiome. Separating what we believe we know and what we truly know about the microbiome is essential to directing research and commercialization efforts. From scoping microbiome-based modalities and sourcing new platforms to identifying regulatory strategies and insights there are a number of steps to development and commercialization from both the industry and startup point of view.

BCF Career Event is the largest career fair for Bio/Life Sciences, Chemistry, Food & Pharma in Belgium. It is the meeting place for everyone who is or wants to be active in the mentioned sectors. BCF Career Event offers you the opportunity to get into direct contact with a broad range of employers in the sector, but also with other organisations that can help you further in your career.

During this international Conference we will focus on how cancer and stromal cells metabolically communicate and how their specific metabolism impacts disease development and progression. These cellular metabolism insights will offer novel therapeutic opportunities for malignant, metabolic, or inflammatory disease. In addition, also the impact of ‘omics’ technologies to study cellular metabolism will be highlighted during the meeting.

With no less than about 20,000 dangerous substances registered at the EU level (ECHA, 2018), the issue of risk assessment and risk communication has evolved to an increasingly challenging task during the last decades. Although vast efforts have been invested in the regulation of physical, chemical and biologically hazardous agents, it should be acknowledged that full knowledge is limited to a relatively small part of an exponentially growing market. Further, the risk perception of stakeholders not only depends on the intrinsic hazard or risk in the first place, but also -and in particularly- on external factors, such as media and lobbying, which place the facts into different contexts.

De Clercq & Partners is happy to announce the programme of our yearly one-day patent seminar, an event that brings together cutting-edge topics and prominent figures from the industry to provide you with the latest developments in Intellectual Property.

Would you like to advance yourself and your career in the BioBusiness? Do you want to increase your insights in the fast-moving Life Sciences industry and gain a better understanding of key success factors for biotech companies? Then join the first edition of the BioBusiness Winter Retreat from 11-13 December in Ghent and invest in your own development and professional career in Life Sciences. This course is part of the recently founded EU-financed Health and Life Science Academy.